source
- Roche and Ionis report positive Phase 3 interim results for IgA nephropathy drug sefaxersenRoche and Ionis announced that their experimental RNA therapy sefaxersen met its primary endpoint in an interim analysis of a Phase 3 trial for IgA nephropathy. The trial showed statistically sign…
- European pharma CEOs warn of biotech decline as R&D share drops to 31% and call for faster trials and stronger IP protectionNine leading European pharma board chairs issued an open letter warning that Europe is losing its biotech edge. They note that Europe's share of global pharma R&D fell from 43% in 1990 to 31% toda…